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Ischemic optic neuropathy is a major cause
of significantly reduced vision (1–3). It may
be arteritic (AAION) or non-arteritic (NA-
AION), anterior or posterior. NA-AION,
the most common form (1–4), is character-
ized clinically by acute, monocular, painless
visual loss with optic disk swelling (5). It is
attributed to an ischemic insult to the optic
nerve followed by an inflammatory reac-
tion (6, 7). The optic nerve head (ONH), is
sensitive to minute changes in blood flow
and therefore very susceptible to vascu-
lar insufficiencies due to altered autoreg-
ulation, vasospasm, and systemic vascular
disease. However, the process leading to
non-arteritic anterior ischemic optic neu-
ropathy (NA-AION) appears to be complex
and multi-factorial (8), and the exact cause
is still unknown.
RISK FACTORS ASSOCIATED WITH
NA-AION
SYSTEMIC CONDITIONS
Non-arteritic anterior ischemic optic neu-
ropathy usually occurs in the presence
of an underlying vascular disease such
as hypertension, diabetes, atherosclerosis,
hypercholesterolemia, and regional vascu-
lar endothelial disorders, all of which pre-
dispose patients to ischemic stroke. In some
cases, NA-AION is the first sign of these
underlying conditions.
The role of a thrombotic tendency in
NA-AION is controversial. Several studies
associated elevated levels of plasma homo-
cysteine and lipoprotein (a) and decreased
levels of vitamin B6 with NA-AION (9–11),
but the yield of a thrombophilic evaluation
in patients with NA-AION, has not been
proven (11, 12). Furthermore, homocys-
teine levels during the acute event appear
to be similar in patients with NA-AION
who are positive or negative for the C677T
MTHFR mutation, which leads to elevated
homocysteine levels (12), and a similar
frequency of the MTHFR mutation was
reported in patients with NA-AION and
the general population (12). These find-
ings suggest that homocysteine level and
the C677T MTHFR polymorphism do not
play a role in the occurrence of NA-AION.
Nocturnal hypotension has long been
implicated as the “final insult” in com-
promised optic disk, leading to NA-AION.
This assumption is based on studies show-
ing that patients taking antihypertensive
medications have a significantly lower
mean nocturnal systolic blood pressure
than normotensive individuals, and have
a larger mean percentage decrease in sys-
tolic, diastolic, and mean blood pressures
during the night (13). Others suggested
that obstructive sleep apnea (OSA) may
play a role in NA-AION owing to the rel-
ative ischemia that occurs during apneic
episodes (14). Waller et al. (15) found that
71–89% of patients with NA-AION also
had OSA, manifested by insomnia, snor-
ing, and chronic fatigue. However, if noc-
turnal hypotension is indeed involved in
NA-AION, the mechanism probably dif-
fers from that of OSA (7, 14, 16–18)
given findings that OSA is not associated
with a nocturnal decrease in blood pres-
sure and the lack of a difference in the
mean nocturnal decrease in blood pres-
sure between patients with NA-AION and
controls (19). Arda et al. (20) proposed
that sleep apnea may not be a risk factor
for NA-AION by itself but rather a con-
tributory factor given its known deleteri-
ous effect on the vascular endothelium in
diabetes, hypertension, and atherosclerosis.
Although OSA can be treated with contin-
uous positive airway pressure, this may not
prevent NA-AION if the causes are multi-
factorial (16).
OPTIC DISK APPEARANCE
A small cup-to-disk ratio (“disk-at-risk”)
may be a risk factor for NA-AION. A study
from the University of Iowa examining 608
consecutive NA-AION patients reported a
significantly smaller cup-to-disk ratio than
in the general population (21), support-
ing earlier findings (22). A postmortem
study of the optic nerve 20 days after acute
presentation of NA-AION yielded no cor-
relation between the configuration of the
infarct and the vascular territory (23). The
morphology was not consistent with dis-
ease of the large or small vessels and seemed
to represent a form of compartment syn-
drome. The authors postulated that in
patients with a smaller disk, compartment
syndrome secondary to the ONH edema
compresses the vasculature of the ONH,
leading to neuropathy. However, enlarged
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optic disk cup in NA-AION patient was
reported (24).
MEDICATIONS
In patients with predisposing factors for
NA-AION, phosphodiesterase-5 (PDE5)
inhibitors used to treat erectile dysfunc-
tion, such as sildenafil, may disturb optic
nerve autoregulation, leading to blood ves-
sel dilatation and ONH edema (25). More
data are still needed to corroborate this
finding. Moreover, it is unclear if these
effects are incidental or associated with
their effects on the ocular circulation (26).
Optic neuropathy was also reported
in 14 of 22 patients being treated with
the antiarrhythmic drug amiodarone (27),
typically bilateral. Upon discontinuation of
amiodarone, only a few cases improved, all
of whom had mild optic nerve dysfunction.
NATURAL HISTORY OF NA-AION
Up to 40% of NA-AION patients
show spontaneous improvement in vision
whereas 5–29% experience a continued
deterioration over a few days or weeks (8,
28). Following this initial phase, further
progression is unusual (28, 29). NA-AION
recurs in the affected eye in 6% of patients
within 2 years and in up to 7.6% within
3 years (30–32).
TREATMENT OF NA-AION
Because the pathologic mechanism of NA-
AION is still unclear, suggestions for treat-
ment are wide-ranging. None of the treat-
ments attempted so far has proved effective
in recovering the visual loss.
MEDICATIONS
Owing to its known anti-thrombotic activ-
ity, aspirin has been suggested for the treat-
ment of patients after an initial event of
NA-AION, in order to reduce the poten-
tial for hemostasis and inflammation and
thereby prevent a recurrence in the fellow
eye (33, 34). However, no significant long-
term benefit was found. Nevertheless, given
aspirin’s proven role in treating cardiovas-
cular risk factors, many clinicians continue
to recommend it for secondary prevention
of NA-AION if not contraindicated (34).
In NA-AION, compression of the optic
nerve vasculature by the edematous ONH
is believed to increase the ischemic insult
and worsen the visual prognosis. Therefore,
attempts to reduce the ONH edema in the
early stages of the disease with aggressive
oral or intravitreally injected steroids were
carried (2, 35, 36), but the results were
disappointing. One study compared the
outcome of 613 consecutive patients who
voluntarily opted for either systemic corti-
costeroid treatment or no treatment (37).
Among those with visual acuity up to 20/70
within 2 weeks of disease onset, rates of
visual improvement after 6 months were
69.8% for the treated patients and 40.5%
for the untreated patients. Among those
with a moderate to severe initial visual field
defect, corresponding rates were 40.1 and
24.5%. In another trial, patients who were
treated with intravitreal triamcinolone to
improve ONH edema in the acute phase
of NA-AION exhibited more improve-
ment in visual acuity and visual field at
6 months than patients who were not (38–
40). However, none of these findings (37–
40) have been confirmed in a large ran-
domized controlled trial. Indeed, in a state-
ment on the steroid controversy in NA-
AION, researchers concluded that the data
so far on intravitreal steroid treatment
are at best anecdotal and at worst, poten-
tially dangerous or misleading (41). Clin-
icians also need to take into account that
corticosteroids may have significant sys-
temic side effects, especially in elderly or
vasculopathic patients (41).
The administration of bevacizumab,
an anti-vascular endothelial growth fac-
tor antibody, to patients with NA-AION
yielded satisfactory results in few cases
(42). However, there are reports of NA-
ION association with intravitreal beva-
cizumab use (43), and data from con-
trolled randomized studies are lacking for
this indication.
SURGERY
The ischemic optic neuropathy decom-
pression study (IONDT), prompted by
the compartment syndrome theory, indi-
cated that decompression surgery was
no better than careful follow-up. The
43% improvement in patients with care-
ful follow-up as compared to 33% in
the surgery group, with visual loss dur-
ing the 6 months follow-up (12 vs. 24%,
respectively), revealing that decompression
surgery was harmful (44).
CONTROL OF RISK FACTORS
Considering the poor results of treat-
ments directed at the optic disk edema
and inflammation associated with NA-
ION, one of the best options at present is
to control and correct any vasculopathic
risk factors, such as severe hypertension,
hyperglycemia, and hypercholesterolemia.
Although these measures have not been
proven to prevent a sequential acute event
of NA-AION, they will likely improve the
patients’ overall health.
ANIMAL MODELS OF NA-AION: THE
FUTURE TARGETS OF MEDICAL
TREATMENT
Rodent and primate models of NA-AION
have been developed to further under-
standing of the mechanisms underlying
the disease (45–47). The models reproduce
some signs of NA-AION across species,
namely, ONH edema and loss of capillary
perfusion in the optic nerve immediately
behind the globe (but not in the retinal
vessels), and all show long-term apopto-
sis of the retinal ganglion cells (RGCs)
due to loss of axoplasmic transport in the
damaged optic nerve (48, 49). The appear-
ance of the fundus after injury in pri-
mates is very similar to that in humans,
with ONH swelling and flame-like hemor-
rhages (49).
Rodent models of AION (rAION)
have so far proved invaluable for test-
ing potential novel treatments. Hyper-
baric oxygen administered during the crit-
ical period immediately after induction
of injury proved effective in preventing
RGC loss (50). Intravenous or intravitreous
prostaglandin J2 proffered almost equal
protection when administered 5 h before
rAION injury or immediately after, sug-
gesting that it may have an even longer
therapeutic window in humans in whom
the injury develops more slowly, with
episodes of recurring ONH edema (51, 52).
Prostaglandin J2 is currently being tested
in a primate model (Bernstein, 2014, per-
sonal communication). Others reported
that subcutaneous granulocyte colony-
stimulating factor (G-CSF) had both anti-
apoptotic effects on the RGCs and anti-
inflammatory effects on the optic nerve
(53). Experiments in models of optic nerve
crush (ONC), which induces severe edema
in the ONH while allowing for exam-
ination of loss of microvascular perfu-
sion and RGC death, show a protective
effect of G-CSF when administered after
injury (54, 55).
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Clinical findings on the benefit of beva-
cizumab were supported in a murine
model of ONC, showing that the drug pre-
served the integrity of the microvasculature
(56). This apparently prevented post-ONC
ischemia from spreading from the site of
injury to the immediate retrobulbar por-
tion of the nerve. Accordingly, experimen-
tal studies of intravitreal brimonidine, a
peripherally acting α2 adrenergic agonist,
reported an increase in short-term RGC
survival after ONC (57). However, this
effect is paradoxical: in glaucoma, brimoni-
dine was found to reduce aqueous humor
production by inducing vasoconstriction,
whereas in rAION, the decreased RGC
loss would be expected to be secondary to
improved perfusion. Furthermore, a study
conducted to evaluate the effects of bri-
monidine on AION revealed worse vision
in those who received brimonidine (58).
Therefore, brimonidine in the ONC setting
may promote axonal growth (59) rather
than affect vasoactivity, protect the RGCs
in conditions of elevated intraocular pres-
sure (60), and increase levels of brain-
derived neurotrophic factor (BDNF) (61).
There are as yet no studies of the effect
of brimonidine on the oligodendrocytes,
which are necessary for optic nerve axonal
health and are directly injured by ONC.
Brimonidine may be generally protective
when axonal regrowth is required after
rAION.
It is noteworthy, however, that findings
of enhanced RGC survival after rAION
(62) following pretreatment with brimoni-
dine were not replicated in models of
NA-AION (58, 63). Furthermore, the sud-
den onset of NA-AION and the typi-
cally delayed diagnosis make brimonidine
pretreatment for NA-AION impractical,
although translating from bench to clinic,
brimonidine might be used prophylacti-
cally in the fellow unaffected eye of patients
with NA-AION.
High doses of estrogen (64) were found
to have no therapeutic value in rAION,
compatible with the lack of gender speci-
ficity in NA-AION outcome, although
women are considered protected until
menopause.
Aside from G-CSF (54, 55), other exoge-
nous compounds were found to have a pro-
tective effect against some aspects of ONC
when administered after injury, includ-
ing α-crystallin (65), BDNF (66–68), the
PPARγ agonist pioglitazone (69), the sir-
tuin 1 (SIRT1) agonist resveratrol (70),
pigment epithelial-derived growth fac-
tor (PEDF) (71), Toll-like receptor 4
(TLR4) antagonists (72), valproate (73),
and endothelin-B antagonists (74). There
is an even larger army of available drugs
for potential pretreatment in ONC injury.
Overall, they are directed against reducing
inflammation or its signaling molecules,
promoting survival or repair of damaged
axons, or preserving patency of the blood
supply. Almost none have been clinically
tested.
SUMMARY
There is still no widely recognized treat-
ment for NA-AION. Evidence from ani-
mal models of NA-AION generally sug-
gests that reducing edema and inflamma-
tion in the acute phase might be effective.
Intravitreal injections are becoming more
commonly used.
The availability of drugs and the direct
approach into the eye may be the best
approach to therapy during the acute
phase, allowing support for the injured
RGCs. Improving RGC survival and reduc-
ing axonal damage after NA-AION is
an active topic of investigation, direct-
ing future goals of neuronal regener-
ation or retinal neurogenesis. Cellular
therapy, either by systemic transplanta-
tion or intravitreous administration, might
become the next mode of treatment to
improve visual outcome in NA-AION.
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